Inhibitors of the PI3K/AKT/mTORcomponents of the EMT signaling pathway, cell cycle, and VEGF signaling havebeen approved for the treatment of kidney carcinoma (mTOR inhibitorstemsirolimus and everolimus) [255],relapses of lymphoma resistant to other types of therapy, and chroniclymphocytic leukemia, in combination with rituximab (idelalisib, a PI3Kinhibitor) [256]. The gene discussed is MTOR; the disease is renal carcinoma.